The Journal for Nurse Practitioners
Volume 2, Issue 9 , Pages S621-S632 , October 2006

Long-Term Pharmacotherapy in the Management of Chronic Insomnia

  • Andrew D. Krystal

      Affiliations

    • Andrew D. Krystal, MD, MS, is associate professor with tenure in the Department of Psychiatry at Duke University Medical Center. He directs the Sleep Research Laboratory and Insomnia Program. He is board certified in psychiatry, sleep medicine, and clinical neurophysiology and works primarily in the areas of sleep and mood disorders. He has research grant support from NIH, Sepracor, Pfizer, Merck, Somaxon, Neurocrine, GlaxoSmithKline, Sanofi-Aventis, Cephalon, and Respironics. He serves as a consultant for Sepracor, Somaxon, Neurocrine GlaxoSmithKline, Pfizer, Sanofi-Aventis, Cephalon, Respironics, Neurogen, Transoral, Takeda, Johnson & Johnson, Lilly, King, and Organon and is a speaker for Sepracor and Sanofi-Aventis.
    • ,
  • Shari Rogers

      Affiliations

    • Shari Rogers, MSN, CRNP, ACNP-BC, is a board-certified acute care nurse practitioner with the Sleep Medicine Center at the University of Pittsburgh Medical Center. She also serves as adjunct faculty for the Acute Care Nurse Practitioner Program at the University of Pittsburgh School of Nursing.
    • ,
  • Margaret A. Fitzgerald

      Affiliations

    • Margaret A. Fitzgerald, MS, APRN, BC, NP-C, FAANP, CSP, is the president of Fitzgerald Health Education Associates, Inc. in North Andover, Mass, and a board-certified family nurse practitioner and Certified Speaking Professional. She is a family practice provider at the Greater Lawrence (Mass) Family Health Center where she also serves as adjunct faculty to the Health Center's Family Practice Residency Program. She has relationships with Sepracor, GlaxoSmithKline, Janssen Ortho-McNeil, and Schwarz Pharma.

References 

  1. Roth T . New developments for treating sleep disorders . J Clin Psychiatry . 2001;62(Suppl 10):3–4
  2. Foley DJ , Monjan AA , Brown SL , Simonsick EM , Wallace RB , Blazer DG . Sleep complaints among elderly persons: an epidemiologic study of three communities . Sleep . 1995;18(6):425–432
  3. Shochat T , Umphress J , Israel AG , Ancoli-Israel S . Insomnia in primary care patients . Sleep . 1999;22(Suppl 2):S359–S365
  4. Simon GE , VonKorff M . Prevalence, burden, and treatment of insomnia in primary care . Am J Psychiatry . 1997;154(10):1417–1423
  5. Katz DA , McHorney CA . Clinical correlates of insomnia in patients with chronic illness . Arch Intern Med . 1998;158(10):1099–1107
  6. Ohayon MM , Partinen M . Insomnia and global sleep dissatisfaction in Finland . J Sleep Res . 2002;11(4):339–346
  7. Buysse DJ , Reynolds CF , et al.   Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial . Sleep . 1994;17(7):630–637
  8. Bixler EO , Kales A , Soldatos CR , Kales JD , Healey S . Prevalence of sleep disorders in the Los Angeles metropolitan area . Am J Psychiatry . 1979;136(10):1257–1262
  9. Vollrath M , Wicki W , Angst J . The Zurich study. VIII. Insomnia: association with depression, anxiety, somatic syndromes, and course of insomnia . Eur Arch Psychiatry Neurol Sci . 1989;239(2):113–124
  10. Zeitlhofer J , Rieder A , Kapfhammer G , et al.   Epidemiology of sleep disorders in Austria . Wiener klinische Wochenschrift . 1994;106(3):86–88
  11. Hohagen F , Kappler C , Schramm E , Riemann D , Weyerer S , Berger M . Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening—temporal stability of subtypes in a longitudinal study on general practice attenders . Sleep . 1994;17(6):551–554
  12. National Sleep Foundation. 1999 Omnibus Sleep in America poll. 1999.
  13. Hyyppa MT , Kronholm E , Alanen E . Quality of sleep during economic recession in Finland: a longitudinal cohort study . Soc Sci Med . 1997;45:731–738
  14. Chevalier H , Los F , Boichut D , et al.   Evaluation of severe insomnia in the general population: results of a European multinational survey . J Psychopharmacol . 1999;13(4 suppl 1):S21–S24
  15. Hohagen F , Rink K , Kappler C , et al.   Prevalence and treatment of insomnia in general practice. A longitudinal study . Eur Arch Psychiatry Clin Neurosci . 1993;242(6):329–336
  16. Krystal AD . The changing perspective on chronic insomnia management . J Clin Psychiatry . 2004;65(Suppl 8):20–25
  17. Physicians' Desk Reference . Montvale, NJ: Thomson PDR; 2004;
  18. National Institutes of Health . Consensus conference. Drugs and insomnia. The use of medications to promote sleep . JAMA . 1984;251:2410–2414
  19. Benca RM , Ancoli-Israel S , Moldofsky H . Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations . J Clin Psychiatry . 2004;65(Suppl 8):26–35
  20. Walsh JK , Muehlbach MJ , Lauter SA , Hilliker NA , Schweitzer PK . Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis . J Rheumatol . 1996;23(2):245–252
  21. Benca RM . Consequences of insomnia and its therapies . J Clin Psychiatry . 2001;62(Suppl 10):33–38
  22. Asnis GM , Chakraburtty A , DuBoff EA , et al.   Zolpidem in SSRI-treated patients with persistent insomnia . J Clin Psychiatry . 1999;60(10):668–676
  23. Perlis ML , Giles DE , Buysse DJ , Tu X , Kupfer DJ . Self-reported sleep disturbance as a prodromal symptom in recurrent depression . J Affect Disord . 1997;42(2-3):209–212
  24. Doghramji P . Recognizing sleep disorders in a primary care setting . J Clin Psychiatry . 2004;65(Suppl 16):23–26
  25. Manifestations and management of chronic insomnia in adults. National Institutes of Health State-of-the-Science Conference Statement . Available at: www.nih.gov June 13-15, 2005;
  26. Insomnia: assessment and management in primary care . Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998; (NIH publ no. 98-4088.)
  27. Mellinger G , Balter M , Uhlenhuth E . Insomnia and its treatment: prevalence and correlates . Arch Gen Psychiatry . 1985;42(3):225–232
  28. Klink M , Quan SF , Kaltenborn W , et al.   Risk factors associated with complaints of insomnia in a general adult population: influence of previous complaints of insomnia . Arch Intern Med . 1992;152(8):1634–1637
  29. Roth T , Ancoli-Israel S . Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey II . Sleep . 1999;22(Suppl 2):S354–S358
  30. Brunello N , Armitage R , Feinberg I , et al.   Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment . Neuropsychobiology . 2000;42(3):107–119
  31. Zammit GK , Weiner J , Damato N , Sillup GP , McMillan CA . Quality of life in people with insomnia . Sleep . 1999;22(Suppl 2):S379–S385
  32. Leger D , Guilleminault C , Bader G , Levy E , Paillard M . Medical and socio-professional impact of insomnia . Sleep . 2002;25(6):625–629
  33. Leger D . The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research . Sleep . 1994;17(1):84–93
  34. Weissman MM , Greenwald S , Nino-Murcia G , Dement WC . The morbidity of insomnia uncomplicated by psychiatric disorders . Gen Hosp Psychiatry . 1997;19(4):245–250
  35. Chang PP , Ford DE , Mead LA , Cooper-Patrick L , Klag MJ . Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study . Am J Epidemiol . 1997;146(2):105–114
  36. Breslau N , Roth T , Rosenthal L , Andreski P . Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults . Biol Psychiatry . 1996;39(6):411–418
  37. Leger D , Scheuermaier K , Philip P , Paillard M , Guilleminault C . SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers . Psychosomatic Med . 2001;63(1):49–55
  38. Buysse & Perlis. The evaluation and treatment of insomnia . J Prac Psych Behav Health . 1996;
  39. Bastien CH , Vallieres A , Morin CM . Validation of the Insomnia Severity Index as an outcome measure for insomnia research . Sleep Med . 2001;2(4):297–307
  40. Buysse DJ , Reynolds CF , Monk TH , Berman SR , Kupfer DJ . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research . Psychiatry Res . 1989;28(2):193–213
  41. Doghramji K . Assessment of excessive sleepiness and insomnia as they relate to circadian rhythm sleep disorders . J Clin Psych . 2004;65(Suppl 16):17–22
  42. Walsh JK . Clinical and socioeconomic correlates of insomnia . J Clin Psych . 2004;65(suppl 8):13–19
  43. Strollo PJ , Rogers R . Obstructive sleep apnea . N Engl J Med . 1996;334(2):99–104
  44. Sleep apnea: is your patient at risk? . Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995; (NIH publ no. 95-3805)
  45. Mahowald MW , Schenck CH . Parasomnias including the restless leg syndrome . Clin Chest Med . 1998;19(1):183–202
  46. Practice parameters for the use of polysomnography in the evaluation of insomnia. Standards of Practice Committee of the American Sleep Disorders Association . Sleep . 1995;18(1):55–57
  47. McClusky HY , Milby JB , Switzer PK , Williams V , Wooten V . Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia . Am J Psychiatry . 1991;148(1):121–126
  48. Hauri PJ . Can we mix behavioral therapy with hypnotics when treating insomniacs? . Sleep . 1997;20(12):1111–1118
  49. Edinger JD , Sampson WS . A primary care ‘friendly’ cognitive behavioral insomnia therapy . Sleep . 2003;26(2):177–182
  50. Morin CM , Hauri PJ , Espie CA , Spielman AJ , Buysse DJ , Bootzin RR . Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review . Sleep . 1999;22(8):1134–1156
  51. Nowell PD , Mazumdar S , Buysse DJ , Dew MA , Reynolds CF , Kupfer DJ . Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy . JAMA . 1997;278(24):2170–2177
  52. Buysse D , Dorsey C . Current and experimental therapeutics of insomnia . In:  Davis K ,  Charney D ,  Coyle J ,  Nemeroff C editor. Neuropsychopharmacology: the fifth generation of progress . Philadelphia, Pa: Lippincott Williams & Wilkins; 2002;p. 1932–1944
  53. Morin CM , Colecchi C , Stone J , Sood R , Brink D . Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial . JAMA . 1999;281:991–999
  54. Oswald I , French C , Adam K , Gilham J . Benzodiazepine hypnotics remain effective for 24 weeks . Br Med J . 1982;284(6319):860–863
  55. Walsh JK , Roth T , Randzaao A , et al.   Eight weeks of non-nightly use of zolpidem for primary insomnia . Sleep . 2000;23(8):1087–1096
  56. Walsh JK , Erman M , Erwin CW , et al.   Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia . Hum Psychopharmacol . 1998;13:191–198
  57. Scharf MB , Roth T , Vogel GW , Walsh JK . A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia . J Clin Psychiatry . 1994;55(5):192–199
  58. Ware JC , Walsh JK , Scharf MB , Roehrs T , Roth T , Vogel GW . Minimal rebound insomnia after treatment with 10 mg zolpidem . Clin Neuropharmacol . 1997;20(2):116–125
  59. Fry J , Scharf M , Mangano R , Fujimori M . Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group . Int Clin Psychopharmacol . 2000;15(3):141–152
  60. Elie R , Ruther E , Farr I , Emilien G , Salinas E . Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group . J Clin Psychiatry . 1999;60(8):536–544
  61. Ambien CR [package insert] . New York, NY: Sanofi-Synthelabo; 2005;
  62. Woods JH , Katz JL , Winter G . Abuse and therapeutic use of benzodiazepines and benzodiazepine-like drugs . Am College Neuropsychopharmacology . 1995;
  63. Soyka M , Bottlender R , Moller HJ . Epidemiological evidence for a low abuse potential of zolpidem . Pharmacopsychiatry . 2000;33(4):138–141
  64. Hedner J , Yaech R , Emilien G , et al.   Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia . Int J Geriatr Psychiatry . 2000;15(8):704–712
  65. Ancoli-Israel S , Walsh J , Mangano R , et al.   Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects . Prim Care Companion J Clin Psychiatry . 1999;1(4):114–120
  66. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders . Washington, DC: American Psychiatric Publishing, Inc; 2000; DSM-IV-TR
  67. Krystal AD , Walsh JK , Roth T , Amato DA , Wessel TC . Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia . Sleep . 2003;26(7):793–799
  68. Roth T , Walsh JK , Krystal A , Wessel T , Roehrs TA . An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic insomnia . Sleep Med . 2005;6(6):487–495
  69. Zammit GK , McNabb LJ , Caron J , Amato DA , Roth T . Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia . Curr Med Res Opin . 2004;20(12):1979–1991
  70. Scharf M , Erman M , Rosenberg R , et al.   A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia . Sleep . 2005;28(6):720–727
  71. McCall WV . Sleep in the elderly: burden, diagnosis, and treatment . Prim Care Companion J Clin Psychiatry . 2004;6(1):9–20
  72. Owens JA , Rosen CL , Mindell JA . Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians . Pediatrics . 2003;111(5):e628–e635 (online and updated through 7/7/2005)
  73. Mindell JA . Empirically supported treatments in pediatric psychology: bedtime refusal and night wakings in young children . J Pediatr Psychol . 1990;24:465–481
  74. Walsh JK , Erman M , Erwin CW , et al.   Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia . Hum Psychopharmacol . 1998;13:191–198
  75. Walsh JK , Schweitzer PK . Ten-year trends in the pharmacological treatment of insomnia . Sleep . 1999;22(3):371–375
  76. Rickels K , Morris RJ , Newman H , et al.   Diphenhydramine in insomniac family practice patients: a double-blind study . J Clin Pharmacol . 1983;23(5-6):234–242
  77. Kudo Y , Kurihara M . Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study . J Clin Pharmacol . 1990;30(11):1041–1048
  78. Sunshine A , Zighelboim I , Laska E . Hypnotic activity of diphenhydramine, methapyrilene, and placebo . J Clin Pharmacol . 1978;18(8-9):425–431
  79. Richardson GS , Roehrs TA , Rosenthal L , Koshorek G , Roth T . Tolerance to daytime sedative effects of H1 antihistamines . J Clin Psychopharmacol . 2002;22:511–515
  80. Rozerem [prescribing information]. August 2005.
  81. NDA 21-782 . Available at: www.fda.gov/cder/foi/label/2005/021782lbl.pdf
  82. Hajak G . A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience . Drug Saf . 1999;21(6):457–469
  83. Roehrs T , Pedrosi B , Rosenthal L , Roth T . Hypnotic self administration and dose escalation . Psychopharmacology . 1996;127(2):150–154
  84. Comparison of insomnia treatments . Pharmacists Letter . 2005;21(211015):1

 A.D.K. and M.A.F. received compensation from Sepracor Inc. for the services they provided in support of the development of this manuscript. (S.R. opted not to receive compensation.)

PII: S1555-4155(06)00577-0

doi: 10.1016/j.nurpra.2006.08.003

The Journal for Nurse Practitioners
Volume 2, Issue 9 , Pages S621-S632 , October 2006

Article Tools

* Image Usage & Resolution